Kolexia
Dalle Stephane Dermatologie
Dalle Stephane
Dermatologie
Hôpital Lyon Sud
Pierre-Bénite, France
578 Activités
195 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs cutanées Lymphomes Lymphome T Carcinomes Lymphome T cutané Récidive tumorale locale Mycosis fongoïde Métastase tumorale

Collaborateurs

Voir plus
Thomas Luc
Thomas Luc
Hôpital Lyon Sud, Pierre-Bénite, France
Lebbe Celeste
Lebbe Celeste
Hôpital Saint-Louis, Paris, France
Dalac Sophie
Dalac Sophie
Hôpital François Mitterrand, Dijon, France
Mortier Laurent
Mortier Laurent
Hôpital Huriez, Lille, France

Industries

Voir plus
MSD
10 collaboration(s)
Dernière en 2023
Parexel
3 collaboration(s)
Dernière en 2023
UCB
2 collaboration(s)
Dernière en 2022
BMS
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELATIVITY-127: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Essai Clinique (BMS)   29 février 2024
ODYSSEE: Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
Essai Clinique (Hospices Civils de Lyon)   26 février 2024
Pan Tumor Nivolumab Rollover Study: Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Essai Clinique (BMS)   14 février 2024
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors: A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Essai Clinique (BMS)   06 février 2024
Cancer Cell Biomechanical Properties Accompany Tspan8-Dependent Cutaneous Melanoma Invasion.
Cancers   06 février 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
European journal of cancer (Oxford, England : 1990)   01 février 2024
Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.
European journal of cancer (Oxford, England : 1990)   24 janvier 2024
CheckMate 238: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Essai Clinique (BMS)   05 janvier 2024
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC. CardioOncology   19 décembre 2023
Sphingolipid paracrine signaling impairs keratinocyte adhesion to promote melanoma invasion.
Cell reports   18 décembre 2023